Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.11.5399

Serum Human Leukocyte Antigen-G and Soluble Interleukin 2 Receptor Levels in Acute Lymphoblastic Leukemic Pediatric Patients  

Motawi, Tarek M.K. (Biochemistry Department, Faculty of Pharmacy, National Cancer Institute)
Zakhary, Nadia I. (Cancer Biology Department, National Cancer Institute)
Salman, Tarek M. (Biochemistry Department, Faculty of Pharmacy, National Cancer Institute)
Tadros, Samer A. (Biochemistry Department, Faculty of Pharmacy, National Cancer Institute)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.11, 2012 , pp. 5399-5403 More about this Journal
Abstract
Aims and Background: Human leukocyte antigen-G and interleukin-2 receptor play pivotal roles in the proliferation of lymphocytes, and thus generation of immune responses. Their overexpression has been evidenced in different malignant hematopoietic diseases. This study aimed to validate serum soluble human leukocyte antigen-G (sHLA-G) and serum soluble interleukin-2 receptor (sIL-2R) as an additional tool for the diagnosis and follow up of acute lymphoblastic leukemia (ALL). Subjects and Methods: Both markers were determined by ELISA in the serum of 33 ALL pediatric patients before treatment and after intensification phase of chemotherapy as well as in the serum of 14 healthy donors that were selected as a control group. Results: ALL patients showed abnormal CBC and high serum lactate dehydrogenase, which were improved after chemotherapy. Also, there was a non-significant increase in serum sHLA-G in ALL patients compared with the control group. However, after chemotherapy, sHLA-G was increased significantly compared with before treatment. On the other hand, serum sIL-2R in ALL patients was increased significantly compared with the control group. After chemotherapy, sIL-2R decreased significantly compared with before treatment. Conclusions: From these results it could be suggested that measurement of serum sHLA-G might be helpful in diagnosis of ALL, while sIL-2R might be useful in diagnosis and follow-up of ALL in pediatric patients.
Keywords
Soluble human leukocyte antigen-G; soluble interleukin-2 receptor; acute lymphoblastic leukemia;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Arioz DT, Altindis M, Tokyol C, et al (2009). Human papillomavirus typing and soluble interleukin-2 receptor levels in female sex workers with a negative cervical smear result. Int J of Gynaecol Obstet, 106, 210-2.   DOI
2 Bien E, Balcerska A (2009). Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma. Scand J Immunol, 70, 490-500.   DOI
3 Bien E, Balcerska A (2008). Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers, 13, 1-26.   DOI
4 Bien E, Balcerska A. (2003). Interleukin 2 receptor-the structure, function and clinical significance in malignant diseases of adults and children. Postepy Hig Med Dosw, 57, 669-83.
5 Brito-Babapulle F (2003). The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol, 121, 203-23.   DOI   ScienceOn
6 Cervera I, Herraiz MA, Penaloza J, Vidart J, Martinez-Laso J (2010). A new allele, HLA-G*010120, is generated by a recombination event between HLA-G*01010101/02 and HLA-G*01010201. Tissue Antigens, 75, 738-40.   DOI
7 Eiji O, Tasuke H, Katsumi O, et al (2000). Clinical utility of soluble interleukin-2 receptor in patients with acute lymphoblastic leukemia. Jpn J Med Technol, 49, 1576-9.
8 Elattar I (2007). Cancer statistics, NCI, Egypt 2002-2005.
9 Faderl S, O'Brien S, Pui CH, et al (2010). Adult acute lymphoblastic leukemia: concepts and strategies. Cancer, 1, 1165-76.
10 Fainardi E, Castellazzi M, Stignani M, et al (2011). Emerging topics and new perspectives on HLA-G. Cell Mol Life Sci, 68, 433-51.   DOI
11 Garcia-Tunon I, Ricote M, Ruiz A, et al (2004). Interleukin-2 and its receptor complex (${\alpha}$, ${\beta}$ and ${\gamma}$ chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study. Breast Cancer Res, 6, 1-7.   DOI
12 Gonzalez A, Rebmann V, LeMaoult J, et al (2012). The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci, 49, 63-84.   DOI
13 Hafiz MG, Rahman MM, Mannan MA (2008). Serum lactate dehydrogenase as a prognostic marker of childhood acute lymphoblastic leukemia. Mymensingh Med J, 17, 169-73.
14 HoWangYin K, Caumartin J, Favier B, et al (2011). Proper regrafting of Ig-like transcript 2 after trogocytosis allows a functional cell-cell transfer of sensitivity. J Immunol, 186, 2210-8.   DOI
15 HoWangYin KY, Alegre E, Daouya M, et al (2010). Different functional outcomes of intercellular membrane transfers to monocytes and T cells. Cell Mol Life Sci, 67, 1133-45.   DOI
16 Jo SA, Hwang SH, Chang CL, et al (2010). Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2R${\alpha}$) in patients with non-Hodgkin's lymphoma. Korean J Lab Med, 30, 600-5.   DOI
17 Ksouri H, Bardi R, Mellouli F, Bejaoui M (2009). HLA-G: an immunoregulatory non classical class I HLA molecule. Arch Inst Pasteur Tunis, 86, 27-38.
18 Kasprzak A, Olejniczak K, Przybyszewska W, Zabel M (2007). Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours. Folia Morphol (Warsz), 66, 159-66.
19 Katsuya H, Yamanaka T, Ishitsuka K, et al (2012). Prognostic index for acute-and lymphoma-type adult T-cell leukemia/ lymphoma. J Clin Oncol, 30, 1635-40.   DOI
20 Kitaoka S, Shiota G, Kawasaki H. (2003). Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C. Hepatogastroenterology, 50, 1569-74.
21 Le Discorde M, Moreau P, Sabatier P, Legeais JM and Carosella ED (2003). Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol, 64, 1039-44.   DOI
22 Ling JY, Sun XF, Yan SL, et al (2007). Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases. Ai Zheng, 26, 418-22.
23 Mallet V, Blaschitz A, Crisa L, et al (1999). HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83 dendritic cells expresses HLA-G as a membranebound and soluble protein. Int Immunol, 11, 889-98.   DOI
24 Mitsdoerffer M, Schreiner B, Kieseier BC, et al (2005). Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol, 159, 155-64.   DOI
25 Moon Y, Kim Y, Kim M, et al (2004). Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia. Ann Clin Lab Sci, 34, 410-5.
26 Pui CH (2006). Acute lymphoblastic leukemia, in Childhood Leukemias, 2nd ed. In: Pui CH. Cambridge University Press, New York, p 439.
27 Nakase K, Tsuji K, Tamaki S, et al (2005). Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detect and Prev, 29, 256-9.   DOI
28 Pavlidis NA, Manoussakis MN, Germanidis GS, Moutsopoulos HM (1992). Serum soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies. Med Pediatr Oncol, 20, 26-31.
29 Pistoia V, Morandi F, Wang X, Ferrone S (2007). Soluble HLA-G: Are they clinically relevant. Semin Cancer Biol, 17, 469-79.   DOI
30 Pui CH, Evans WE (2006). Treatment of acute lymphoblastic leukemia. N Engl J Med, 354, 166-78.   DOI
31 Rebmann V, Switala M, Eue I, Grosse-Wilde H (2010). Soluble HLA-G is an independent factor for the prediction of pregnancy outcome after ART: a German multi-centre study. Hum Reprod, 25, 1691-8.   DOI
32 Rizzo R, Vercammen M, van de Velde H, Horn PA, Rebmann V (2011). The importance of HLA-G expression in embryos, trophoblast cells, and embryonic stem cells. Cell Mol Life Sci, 68, 341-52.   DOI
33 Rouas-Freiss N, Moreau P, Ferrone S and Carosella ED (2005). HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res, 65, 10139-44.   DOI   ScienceOn
34 Sarmento-Ribeiro AB, Proenca MT, Sousa I, et al (2012). A possible role for oxidation stress in lymphoid leukaemias and therapeutic failure. Leuk Res, 36, 1041-8.   DOI
35 Sheshgiri R, Rao V, Mociornita A, Ross HJ, Delgado DH (2010). Association between HLA-G expression and C4d staining in cardiac transplantation. Transplantation, 89, 480-1.   DOI
36 Yan WH (2010). HLA-G expression in hematologic malignancies. Expert Rev Hematol, 3, 67-80.   DOI
37 Singer G, Rebmann V, Chen YC, et al (2003). HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res, 9, 4460-4.
38 Wehner R, Dietze K, Bachmann M, Schmitz M (2011). The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun, 3, 258-63.   DOI
39 Wiendl H, Feger U, Mittelbronn M, et al (2005). Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain, 128, 2689-704.   DOI
40 Yang J, Zhao SL, Yang XL (2012). Expression of HLA-G and IL-10 in patients with acute leukemia. Zhonghua Xue Ye Xue Za Zhi, 33, 135-7.